Key statistics
As of last trade, Oric Pharmaceuticals Inc (4TZ:STU) traded at 9.40, 70.91% above the 52 week low of 5.50 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.10 |
---|---|
High | 9.40 |
Low | 9.10 |
Bid | 9.35 |
Offer | 9.60 |
Previous close | 9.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 70.54m |
Free float | 64.10m |
P/E (TTM) | -- |
Market cap | 723.77m USD |
EPS (TTM) | -1.76 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
- ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
- ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
More ▼